Literature DB >> 2440944

T cell specificity for class II (I-A) and the encephalitogenic N-terminal epitope of the autoantigen myelin basic protein.

S S Zamvil, D J Mitchell, A C Moore, A J Schwarz, W Stiefel, P A Nelson, J B Rothbard, L Steinman.   

Abstract

The role of class II restriction in T cell recognition of an epitope of the autoantigen myelin basic protein (MBP) has been investigated. Encephalitogenic PL/J(H-2u) and (PL/J X SJL/J(H-2s))F1 ((PLSJ)F1) clones, isolated after immunization with intact MBP, recognize the N-terminal 11 amino acid residues of MBP in association with I-Au class II molecules. The synthetic peptide MBP 1-11 has been tested in vivo for induction of EAE. Clinical and histological EAE occurs in PL/J and (PLSJ)F1 mice but not SJL/J. The class II restriction of T cells primed with MBP 1-11 has been examined in primary cultures in vitro. Similar to encephalitogenic T cell clones, isolated after continuous selection in vitro, the population of MBP 1-11-specific proliferative PL/J and (PLSJ)F1 T cells, recognize this epitope in association with I-Au class II molecules. Not all MBP-specific T cell clones which are restricted to I-Au class II molecules cause autoimmune encephalomyelitis. The specificity of these non-encephalitogenic clones has been examined in this report. These clones also recognize MBP 1-11. Thus recognition of an encephalitogenic T cell epitope is not sufficient for induction of EAE.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440944

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Abundant empty class II MHC molecules on the surface of immature dendritic cells.

Authors:  L Santambrogio; A K Sato; F R Fischer; M E Dorf; L J Stern
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

2.  Conformational studies of immunodominant myelin basic protein 1-11 analogues using NMR and molecular modeling.

Authors:  Despina Laimou; Eliada Lazoura; Anastassios N Troganis; Minos-Timotheos Matsoukas; Spyros N Deraos; Maria Katsara; John Matsoukas; Vasso Apostolopoulos; Theodore V Tselios
Journal:  J Comput Aided Mol Des       Date:  2011-11-01       Impact factor: 3.686

Review 3.  Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease.

Authors:  Robert S Fujinami; Matthias G von Herrath; Urs Christen; J Lindsay Whitton
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma.

Authors:  T Olsson; W W Zhi; B Höjeberg; V Kostulas; Y P Jiang; G Anderson; H P Ekre; H Link
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

Review 5.  IL-17 producing T cells in mouse models of multiple sclerosis and rheumatoid arthritis.

Authors:  Bernadette Pöllinger
Journal:  J Mol Med (Berl)       Date:  2012-01-10       Impact factor: 4.599

6.  CD8(+) T cells are not necessary for 1 alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice.

Authors:  Terrence F Meehan; Hector F DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

7.  Experimental lyme arthritis in the absence of interleukin-4 or gamma interferon.

Authors:  C R Brown; S L Reiner
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

Review 8.  Activation pathways that drive CD4+ T cells to break tolerance in autoimmune diseases.

Authors:  Sai Harsha Krovi; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2022-02-10       Impact factor: 10.983

Review 9.  MS as autoimmune disease: myelin antigens.

Authors:  W Fierz
Journal:  Res Immunol       Date:  1989-02

10.  Predominant expression of a T cell receptor V beta gene subfamily in autoimmune encephalomyelitis.

Authors:  S S Zamvil; D J Mitchell; N E Lee; A C Moore; M K Waldor; K Sakai; J B Rothbard; H O McDevitt; L Steinman; H Acha-Orbea
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.